Acción SUNESIS PHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Sunesis Pharmaceuticals, Inc. Nasdaq

Acciones

US8673286014

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
SUNESIS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
Sunesis Pharmaceuticals, Inc. Announces Executive Changes
SUNESIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
Sunesis Pharmaceuticals, Inc.(NasdaqCM:SNSS) dropped from NASDAQ Composite Index
Viracta Therapeutics, Inc. completed the acquisition of Sunesis Pharmaceuticals, Inc. for approximately $100 million in a reverse merger transaction.
SUNESIS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
SUNESIS PHARMACEUTICALS INC : Other Events (form 8-K)
SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS
SUNESIS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form 8-K)
Sunesis Pharmaceuticals, Inc. Announces Board Changes
Sunesis Pharmaceuticals, Inc. Announces Executive Changes
Sunesis Pharmaceuticals, Inc. Announces Executive Changes
SUNESIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS
Sunesis Pharmaceuticals : to Combine with Viracta Therapeutics in All-Stock Deal
SUNESIS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement
Viracta Therapeutics, Inc. executed the Offer Letter to acquire Sunesis Pharmaceuticals, Inc. in a reverse merger transaction
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
SUNESIS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción
  4. Acción
  5. Noticias Sunesis Pharmaceuticals, Inc.
  6. Otros idiomas